Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNCOVER-J: Ixekizumab in Japanese Patients With Moderate-to-Severe Psoriasis
NCT01624233Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ixekizumab in plaque psoriasis, erythrodermic psoriasis (EP), generalized pustular psoriasis (GPP), sponsored by Eli Lilly and Company. Started Jun 2012; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasiserythrodermic psoriasis (EP)generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT01624233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624233.